Lorenza Rimassa

Publications by Year

Research Areas

Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers

Most-Cited Works

• → Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma(2018)2,297 cited
• → Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma(2022)1,333 cited
• → NASH limits anti-tumour surveillance in immunotherapy-treated HCC(2021)1,187 cited
• → Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(2022)572 cited
• → Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study(2012)549 cited
• → Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial(2022)504 cited
• → Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.(2022)393 cited
• → Systemic treatment of hepatocellular carcinoma: An EASL position paper(2021)389 cited
• → Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma(2018)376 cited
• → Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study(2018)342 cited